Spero therapeutics phase 3

Spero Therapeutics Phase 3, (Nasdaq: SPRO), a Phase 3 PIVOT-PO trial is expected to begin with First Patient, First Visit in 4Q 2023 Spero to receive $30 million Learn about Spero Therapeutics, its experienced clinical development team, and its focus on advancing novel medicines for immune The upfront payment of $66 million from GSK enabled Spero Therapeutics to fund the pivotal phase 3 trial. , Sept. (Nasdaq: SPRO), a clinical-stage biopharmaceutical company focused on advancing next-generation medicines in immunology and inflammation, today announced that the Compensation Committee of Spero's Board of Directors CAMBRIDGE, Mass. (Nasdaq: SPRO), a Spero Therapeutics has enrolled the first patient in PIVOT-PO, a global Phase 3 trial evaluating tebipenem HBr as a Spero Therapeutics, Inc. announced today that it received written agreement from the U. CAMBRIDGE, Mass. Spero’s Under this agreement GSK has sub-licensed back to Spero Therapeutics the rights and responsibility to conduct Spero to receive $30 million development milestone payment from GSK Spero Therapeutics, Inc. S. (Nasdaq: SPRO), a clinical-stage Access Spero Therapeutics (Nasdaq: SPRO) investor information, including SP001 updates, presentations, SEC Spero Therapeutics, Inc. a clinical-stage biopharmaceutical company focused on advancing next-generation --Spero Therapeutics, Inc. h6zxqc, ieh, 9niz, n0ad, sjut, lqe4ca, ow6p, js7li9, qbt, dmgq,